Portage Biotech Stock to Reverse Split on Thursday, August 15th (NASDAQ:PRTG)

Shares of Portage Biotech Inc. (NASDAQ:PRTG) are going to reverse split on the morning of Thursday, August 15th. The 1-20 reverse split was announced on Tuesday, August 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, August 14th.

Portage Biotech Trading Down 18.1 %

PRTG traded down $0.03 during midday trading on Tuesday, hitting $0.12. 1,041,854 shares of the company were exchanged, compared to its average volume of 446,650. The firm’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.37. Portage Biotech has a 1-year low of $0.11 and a 1-year high of $3.10. The firm has a market capitalization of $2.19 million, a P/E ratio of -0.01 and a beta of 1.47. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.01.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.